PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515611
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515611
Asia Pacific HIV Injection Market, By Drug Type, By Distribution Channel, By Country - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
REPORT HIGHLIGHT
Asia Pacific HIV Injection Market size was valued at USD 390.93 million in 2023, expanding at a CAGR of 17.03% from 2024 to 2032.
HIV injections are injectable treatments used for managing HIV, a virus that attacks the body's immune system and can progress to AIDS if left untreated. These injections are part of antiretroviral therapy (ART), the standard treatment for HIV. One of the most popular long-acting injectable treatments for HIV is the Cabotegravir and Rilpivirine combination. In 2022, the World Health Organization (WHO) included CAB PrEP in its list of recommended options for HIV prevention, releasing guidelines for its use. By June 2023, CAB PrEP has only received regulatory approval in a few countries, with Australia being the sole country in the Asia-Pacific Region. While HIV infection rates are currently low in many Pacific regions, the potential for rapid spread exists once the virus enters small island populations. Countries such as Bangladesh, East Timor, Japan, Laos, Pakistan, and the Philippines continue to report minimal HIV prevalence, even among high-risk groups. These nations have a unique opportunity to prevent major outbreaks by taking immediate action. The financial support for HIV prevention and treatment, in addition to the existing AUD25 million partnership between UNAIDS and the Australian Government in the Asia Pacific region (2022-2027), signifies an expansion of their ongoing collaboration.
Asia Pacific HIV Injection Market- Market Dynamics
The Asia Pacific HIV Injection Market is anticipated to experience growth due to the increasing prevalence of HIV/AIDS and the growing demand for effective treatment options.
The increasing number of HIV/AIDS cases in the Asia Pacific region is creating a need for effective treatment options, including HIV injections. According to a Chinese medical journal, China has managed to keep the epidemic to less than 0.1% of HIV prevalence by the end of 2017. By October 2020, there were 1.045 million reported cases of people living with HIV/AIDS in China. As awareness about HIV/AIDS grows, there is a rising demand for efficient treatment options. HIV injections, such as long-acting antiretroviral therapies (ART), offer an alternative to daily oral medications, providing convenience and improved treatment adherence. Additionally, advancements in drug delivery systems and the development of long-acting injectables (LAIs) present significant growth opportunities for the market. However, the high cost of HIV injections and treatment may hinder market growth.
Asia Pacific HIV Injection Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 17.03% over the forecast period (2024-2032)
Based on Drug Type segmentation, polyethylene was predicted to show maximum market share in the year 2023
Based on Distribution Channel segmentation, automotive was the leading type in 2023
Based on countries, China was the leading revenue generator in 2023
Asia Pacific HIV Injection Market- Segmentation Analysis:
The Asia Pacific HIV Injection Market is segmented based on Drug Type, Distribution Channel, and Country.
The Asia Pacific HIV Injection market categorizes drugs into three groups: Antiretroviral therapy (ART), Pre-exposure Prophylaxis (PrEP), and Long-acting Injectables. ART injections aim to manage HIV and halt the development of AIDS. PrEP injections are utilized to prevent HIV transmission in at-risk communities. , Long-acting injectables offer continuous medication release, decreasing dosing frequency and enhancing patient adherence. They serve both as treatment and prevention for HIV.
The market is segmented into three categories according to Distribution channels: Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. The dominant category is others, which encompasses online pharmacies, community health centers, and NGOs, and is increasingly dominating the distribution channel for HIV injections.
Asia Pacific HIV Injection Market- Geographical Insights
The examination of the HIV Injection market in the Asia Pacific region covers countries such as India, China, South Korea, Japan, Australia, Thailand, Indonesia, and the Philippines, in addition to the rest of the Asia Pacific (APAC). Leading the market is China, attributed to the existence of specialized HIV treatment initiatives and healthcare experts. China has established extensive HIV treatment programs, especially in metropolitan areas and areas with elevated prevalence rates.
Asia Pacific HIV Injection Market- Competitive Landscape:
The competitive landscape of the Asia Pacific HIV Injection market is influenced by rapid urbanization and the development of healthcare infrastructure in countries like China, India, and Indonesia. This presents growth opportunities for providers of HIV injections. In this robust market, companies that innovate in drug delivery, expand their market reach through strategic partnerships and effectively navigate regulatory landscapes are likely to succeed in meeting the increasing demand for effective HIV/AIDS treatments in the region. Additionally, companies are investing in novel drug delivery technologies, such as long-acting injectables, to improve patient compliance and treatment efficacy.
Recent Developments:
GSK plc has revealed that ViiV Healthcare, the HIV Company primarily owned by GSK, with Pfizer and Shionogi as shareholders, has presented 64 abstracts at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver, Colorado. The abstracts include updates on the company's next-generation pipeline advancements, as well as data from its varied portfolio of marketed HIV treatment and prevention options.
On June 20, 2024, Gilead Sciences, Inc. released the top-line findings from an interim analysis of its critical Phase 3 PURPOSE 1 trial. The results revealed that the company's lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, showed 100% effectiveness in the investigational use of HIV prevention in cisgender women.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
ASIA PACIFIC HIV INJECTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT
GlaxoSmithKline PLC (GSK)
Gilead Sciences, Inc.
Cipla Limited
Aurobindo Pharma
Sun Pharmaceutical Industries Ltd.
Mylan N.V.
Dr. Reddy's Laboratories
Boehringer Ingelheim International GmbH
AbbVie, Inc.
Brii Biosciences Limited
Shionogi & Co., Ltd.
Others
ASIA PACIFIC HIV INJECTION MARKET, BY DRUG TYPE - MARKET ANALYSIS, 2019 - 2032
Antiretroviral therapy (ART)
Pre-exposure Prophylaxis (PrEP)
Long-acting Injectable
ASIA PACIFIC HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
Hospital Pharmacy
Drugs Stores & Retail Pharmacies
Others
ASIA PACIFIC HIV INJECTION MARKET, BY COUNTRY- MARKET ANALYSIS, 2019 - 2032
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Table of Contents
1. Asia Pacific HIV Injection Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Asia Pacific HIV Injection Market Snippet by Drug Type
- 2.1.2. Asia Pacific HIV Injection Market Snippet by Distribution Channel
- 2.1.3. Asia Pacific HIV Injection Market Snippet by Country
- 2.2. Competitive Insights
3. Asia Pacific HIV Injection Key Market Trends
- 3.1. Asia Pacific HIV Injection Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Asia Pacific HIV Injection Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Asia Pacific HIV Injection Market Opportunities
- 3.4. Asia Pacific HIV Injection Market Future Trends
4. Asia Pacific HIV Injection Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Asia Pacific HIV Injection Market: COVID-19 Impact Analysis
- 5.1. Pre-COVID-19 Impact Analysis
- 5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments
6. Asia Pacific HIV Injection Market Landscape
- 6.1. Asia Pacific HIV Injection Market Share Analysis, 2023
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Asia Pacific HIV Injection Market - By Drug Type
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
- 7.1.2. Antiretroviral therapy (ART)
- 7.1.3. Pre-exposure Prophylaxis (PrEP)
- 7.1.4. Long-acting Injectable
8. Asia Pacific HIV Injection Market - By Distribution Channel
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
- 8.1.2. Hospital Pharmacy
- 8.1.3. Drugs Stores & Retail Pharmacies
- 8.1.4. Others
9. Asia Pacific HIV Injection Market- By Geography
- 9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
- 9.2. Asia Pacific (APAC)
- 9.2.1. Overview
- 9.2.2. Asia Pacific HIV Injection Key Manufacturers in Asia Pacific
- 9.2.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 9.2.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.6. India
- 9.2.6.1. Overview
- 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.6.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 9.2.6.4. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.7. China
- 9.2.7.1. Overview
- 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.7.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 9.2.7.4. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.8. Japan
- 9.2.8.1. Overview
- 9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.8.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 9.2.8.4. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.9. South Korea
- 9.2.9.1. Overview
- 9.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 9.2.9.4. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.10. Australia
- 9.2.10.1. Overview
- 9.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.10.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 9.2.10.4. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.11. Thailand
- 9.2.11.1. Overview
- 9.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.11.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 9.2.11.4. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.12. Indonesia
- 9.2.12.1. Overview
- 9.2.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.12.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 9.2.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.13. Philippines
- 9.2.13.1. Overview
- 9.2.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.13.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 9.2.13.4. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.14. Rest of APAC
- 9.2.14.1. Overview
- 9.2.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.14.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 9.2.14.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10. Key Vendor Analysis- Asia Pacific HIV Injection Industry
- 10.1. Competitive Dashboard
- 10.2. Company Profiles
- 10.2.1. GlaxoSmithKline PLC (GSK)
- 10.2.2. Gilead Sciences, Inc.
- 10.2.3. Cipla Limited
- 10.2.4. Aurobindo Pharma
- 10.2.5. Sun Pharmaceutical Industries Ltd.
- 10.2.6. Mylan N.V.
- 10.2.7. Dr. Reddy's Laboratories
- 10.2.8. Boehringer Ingelheim International GmbH
- 10.2.9. AbbVie, Inc.
- 10.2.10. Brii Biosciences Limited
- 10.2.11. Shionogi & Co., Ltd.
- 10.2.12. Others
11. 360 Degree Analyst View
12. Appendix
- 12.1. Research Methodology
- 12.2. References
- 12.3. Abbreviations
- 12.4. Disclaimer
- 12.5. Contact Us
List of Tables
- TABLE List of data sources
- TABLE Market drivers; Impact Analysis
- TABLE Market restraints; Impact Analysis
- TABLE Asia Pacific HIV Injection Market: Drug Type Snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by Drug Type
- TABLE Asia Pacific HIV Injection Market, by Drug Type 2019-2032 (USD Million)
- TABLE Asia Pacific HIV Injection Market: Distribution Channel Snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
- TABLE Asia Pacific HIV Injection Market, by Distribution Channel 2019-2032 (USD Million)
- TABLE Asia Pacific Asia Pacific HIV Injection Market, by Country, 2019-2032 (USD Million)
List of Figures
- FIGURE Asia Pacific HIV Injection Market Segmentation
- FIGURE Market research methodology
- FIGURE Value chain analysis
- FIGURE Porter's Five Forces Analysis
- FIGURE Market Attractiveness Analysis
- FIGURE COVID-19 Impact Analysis
- FIGURE Pre & Post COVID-19 Impact Comparision Study
- FIGURE Competitive Landscape; Key company market share analysis, 2023
- FIGURE Drug Type segment market share analysis, 2023 & 2032
- FIGURE Drug Type segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
- FIGURE Distribution Channel segment market share analysis, 2023 & 2032
- FIGURE Distribution Channel segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
- FIGURE Asia Pacific Asia Pacific HIV Injection Market share and leading players, 2023
- FIGURE Asia Pacific Asia Pacific HIV Injection Market share analysis by country, 2023
- FIGURE India Asia Pacific HIV Injection Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
- FIGURE China Asia Pacific HIV Injection Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
- FIGURE Japan Asia Pacific HIV Injection Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
- FIGURE South Korea Asia Pacific HIV Injection Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
- FIGURE Australia Asia Pacific HIV Injection Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
- FIGURE Thailand Asia Pacific HIV Injection Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
- FIGURE Indonesia Asia Pacific HIV Injection Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
- FIGURE Philippines Asia Pacific HIV Injection Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
- FIGURE Rest of APAC Asia Pacific HIV Injection Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
